F. Dubin

发表

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

M. Beksac, K. Anderson, M. Dimopoulos, 2019, Journal of Clinical Oncology.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

J. Machiels, M. Campone, X. Pivot, 2011, European journal of cancer.

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

J. Laubach, P. Richardson, S. Tuchman, 2021, Leukemia.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

M. Beksac, M. Dimopoulos, B. Pégourié, 2019, The Lancet.

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).

P. Richardson, N. Raje, S. Usmani, 2018 .

Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

M. Dimopoulos, P. Richardson, P. Moreau, 2021 .

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

N. Raje, S. Usmani, W. Bensinger, 2019, Blood.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

M. Dimopoulos, P. Richardson, P. Moreau, 2022, The Lancet. Oncology.

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

P. Richardson, N. Raje, S. Usmani, 2016 .

S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

M. Dimopoulos, P. Richardson, P. Moreau, 2019, HemaSphere.

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results.

J. Machiels, M. Campone, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

J. Machiels, M. Campone, X. Pivot, 2009 .

Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)

P. Richardson, S. Usmani, W. Bensinger, 2017 .

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

M. Cavo, A. Perrot, J. Minařík, 2024, Haematologica.